ATF2 Phosphorylation Drives Neuronal Apoptosis in Neurodegenerative Disease Models

Unraveling Neuronal Cell Death in Neurodegeneration

Neurodegenerative diseases such as Alzheimer's and Parkinson's are fundamentally characterized by the progressive loss of neurons, a process often driven by programmed cell death, or apoptosis [1, 2]. This neuronal demise is the direct cause of the debilitating symptoms and irreversible functional decline affecting millions of patients globally [3]. While research has implicated factors like neuroinflammation, oxidative stress, and protein aggregation, the precise molecular cascades that initiate and execute neuronal apoptosis remain incompletely understood [4, 5, 6]. This knowledge gap has hindered the development of therapies that can halt or reverse neurodegeneration. A recent study, however, provides new clarity by identifying a critical transcriptional driver of this cell death pathway, offering a more specific target for future interventions [1].

Identifying Key Players in Neuronal Demise

To pinpoint the specific genes essential for neuronal apoptosis, researchers employed an unbiased, genome-wide CRISPR inhibition screen in human neurons. This technique systematically silences thousands of individual genes one by one, allowing for the identification of those whose absence prevents a particular outcome, in this case, cell death. The screen's comprehensive nature revealed numerous genes required for neuronal apoptosis, some already known and many previously unrecognized in this context. From this large dataset, three molecules stood out as central components of a pro-death cascade: dual leucine zipper kinase (DLK, also known as MAP3K12), the well-known transcription factor JUN, and a lesser-known transcription factor, activating transcription factor 2 (ATF2). The identification of this trio provided a focused starting point for dissecting the specific signaling events that commit a neuron to apoptosis.

ATF2 Phosphorylation: A Critical Transcriptional Switch

Subsequent mechanistic work clarified the sequence of events within this newly identified cell death cascade. The investigators determined that the phosphorylation of activating transcription factor 2 (ATF2) by MAP3 kinases is a critical and indispensable step in neuronal apoptosis. Phosphorylation, the addition of a phosphate group to a protein, often acts as a molecular switch that alters protein function, and in this case, it activates ATF2's pro-death activity. In a finding that refines previous models, the study also showed that direct JUN phosphorylation is not required for the apoptotic process to proceed. Instead, the researchers established a clear hierarchy: the MAP3 kinase signal is converted into a pro-apoptotic transcriptional response when the newly phosphorylated ATF2 upregulates the expression of the JUN gene. This positions phospho-ATF2 as the key intermediary that translates an upstream kinase signal into the downstream genetic program for cell death.

Clinical Implications: Preventing Neuronal Loss

The identification of ATF2 phosphorylation as an essential node in neuronal apoptosis has direct therapeutic relevance. The researchers provided functional proof by demonstrating that interfering with ATF2 function prevents neuronal apoptosis in both in vitro cell cultures and in vivo models. This confirmation in living organisms underscores the pathway's significance beyond the laboratory bench. These findings posit ATF2 as a specific molecular target for intervention. Unlike broad neuroprotective strategies, a therapy designed to inhibit ATF2 phosphorylation could offer a precise mechanism for slowing disease progression across a range of neurodegenerative disorders characterized by apoptosis. By targeting a key executioner of cell death, such an approach holds the potential to preserve neuronal integrity and function, directly addressing the underlying pathology of these conditions.

References

1. Guo J, Huang X, Dou L, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-01251-0

2. Gómez-Deza J, Nebiyou M, Touny LHE, et al. ATF2 phosphorylation is a core transcriptional driver of neuron apoptosis.. Neuron. 2026. doi:10.1016/j.neuron.2026.04.035

3. Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01486-5

4. Pacher P, Beckman JS, Liaudet L. Nitric Oxide and Peroxynitrite in Health and Disease. Physiological Reviews. 2007. doi:10.1152/physrev.00029.2006

5. ALNasser MN, Mellor IR, Carter WG. Is L-Glutamate Toxic to Neurons and Thereby Contributes to Neuronal Loss and Neurodegeneration? A Systematic Review. Brain Sciences. 2022. doi:10.3390/brainsci12050577

6. Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01588-0